CORREALE, MICHELE
 Distribuzione geografica
Continente #
EU - Europa 1.569
NA - Nord America 1.242
AS - Asia 366
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
AF - Africa 1
OC - Oceania 1
Totale 3.185
Nazione #
US - Stati Uniti d'America 1.240
IE - Irlanda 642
SE - Svezia 363
UA - Ucraina 270
CN - Cina 223
IT - Italia 106
SG - Singapore 63
AT - Austria 51
IN - India 49
CZ - Repubblica Ceca 41
FI - Finlandia 34
TR - Turchia 29
DE - Germania 22
FR - Francia 20
GB - Regno Unito 10
NL - Olanda 3
CA - Canada 2
ES - Italia 2
EU - Europa 2
JP - Giappone 2
PE - Perù 2
RU - Federazione Russa 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BR - Brasile 1
EG - Egitto 1
HR - Croazia 1
PL - Polonia 1
RO - Romania 1
Totale 3.185
Città #
Dublin 642
Nyköping 233
Chandler 187
Jacksonville 170
Ashburn 162
Dearborn 72
Princeton 61
Nanjing 60
Vienna 51
New York 47
Wilmington 45
Singapore 40
Beijing 36
Seattle 29
Brno 28
Boardman 27
Helsinki 23
Nanchang 22
Pune 22
San Mateo 17
Rome 15
Tianjin 15
Des Moines 14
Olomouc 13
Los Angeles 12
Munich 11
Shenyang 11
Foggia 9
Jiaxing 8
Renton 8
Washington 8
Changsha 7
Hangzhou 7
Kunming 7
Lund 7
Palermo 7
Stevenage 7
Woodbridge 7
Ann Arbor 6
Gesualdo 6
Guangzhou 6
Hebei 6
Jinan 6
Acerra 5
Bari 5
Ningbo 5
Changchun 4
Lanzhou 4
Messina 4
Norwalk 4
Philadelphia 4
San Severo 4
Apricena 3
Bisceglie 3
Borås 3
Martina Franca 3
Redwood City 3
Shanghai 3
Stimigliano 3
Taglio Di Po 3
Zhengzhou 3
Augusta 2
Hanover 2
Hefei 2
Hilden 2
Kolkata 2
Lima 2
Naples 2
New Delhi 2
Orange 2
Rockville 2
Taizhou 2
Valle 2
Agordo 1
Andria 1
Aprilia 1
Arzano 1
Benetutti 1
Bitonto 1
Cairo 1
Chengdu 1
Cirié 1
Clearwater 1
Dallas 1
Fuzhou 1
Glasgow 1
Haikou 1
Hubert 1
Hunedoara 1
Jackson 1
Kilcoy 1
Latina 1
Leawood 1
London 1
Milan 1
Novokuznetsk 1
Oristano 1
Paris 1
Peschici 1
Porto 1
Totale 2.294
Nome #
Alcohol-induced cardiac disease 94
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 82
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 82
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 80
Cardiopulmonary exercise test predicts right heart catheterization 80
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 78
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 73
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 73
Chronic thromboembolic pulmonary hypertension. 73
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 73
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 73
Delirium in heart failure 70
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 68
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 67
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 67
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 67
Redefining biomarkers in heart failure 67
Liver disease and heart failure: Back and forth 67
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 64
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 60
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 59
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 59
COMPASS vs PEGASUS approach in a comparative budget impact analysis 58
HIV-associated pulmonary arterial hypertension: from bedside to the future 56
"ischemic" ST elevation in a woman with left ventricular hypertrophy 56
Biomarkers in cardiorenal syndrome 54
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 53
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 53
Liver disease and heart failure: an uptodate 52
Advanced heart failure: non-pharmacological approach 51
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 51
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 51
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 50
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 49
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 46
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 45
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 45
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 44
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 44
The thromboembolism in COVID-19: the unsolved problem 43
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 43
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 42
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 42
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 40
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 40
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 39
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 38
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 37
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 37
New Targets in Heart Failure Drug Therapy 37
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 36
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 36
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 36
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 35
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 34
Delirium in heart failure 34
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 33
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 33
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 30
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 30
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 29
Effects of Sacubitril/Valsartan on the Renal Resistance Index 24
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 21
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 21
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 18
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 15
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 14
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 13
Flow Mediated Dilation in Systemic Sclerosis: Association with clinical findings, capillaroscopic patterns and endothelial circulating markers 13
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 11
Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function 10
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 7
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest 6
Relationship between the strain measures of left atrial function and heart failure worsening 6
The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction 6
Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach 6
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 5
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy 5
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 5
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience 5
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction 5
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus 5
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets 4
Alcohol consumption and subclinical and clinical coronary heart disease: New insight into potential causal mechanisms 4
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 4
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 4
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 4
Imaging Modality to Guide Left Atrial Appendage Closure: Current Status and Future Perspectives 3
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study 3
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis 3
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? 3
Totale 3.491
Categoria #
all - tutte 23.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.963


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020382 68 28 6 2 40 51 67 9 50 14 44 3
2020/2021371 50 7 42 12 43 3 51 54 52 56 1 0
2021/2022412 17 2 11 3 70 14 11 38 49 86 6 105
2022/20231.331 117 69 83 38 31 104 2 86 702 10 40 49
2023/2024585 57 18 39 19 79 124 13 94 1 11 14 116
2024/202526 26 0 0 0 0 0 0 0 0 0 0 0
Totale 3.491